Abstract
The behavioral profile of a range of adenosine receptor ligands was examined in rats using a locomotor activity model. Adenosine receptor agonists, including the selective A1 receptor agonist, N6-cyclopentyladenosine (CPA) and the A2A agonist, 2-[(2-aminoethylamino)carbonylethyl-phenylethylamino]-5′-ethylcarboxamidoadenosine (APEC), reduced spontaneous motor activity in a dose-dependent manner. CPA-induced locomotor depression was attenuated by adenosine A1 receptor selective antagonists, such as 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-acryloyl]-2-piperidine ethanol (FK453), and (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-acryloyl]-piperidin-2-yl acetic acid (FK352), but not by the A2A receptor antagonist, (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine (KF17837). By contrast, APEC-induced hypolocomotion was attenuated by KF17837 but not by DPCPX, confirming that adenosine A1 and A2A receptor activation mediates locomotor output independently. It was found that two peripheral adenosine receptor antagonists, 8-(p-sulphophenyl)-1,3-dipropylxanthine (DPSPX) and 8-(p-sulphophenyl)-1,3-dimethylxanthine (8-PST), did not alter CPA-induced hypolocomotion. This confirmed that pharmacological reversal of the adenosine A1 receptor-mediated response involved a central site of drug action. The relationship between occupancy of central adenosine A1 receptors and behavioral effect was therefore assessed. Regression analysis on log transformed data confirmed associations between antagonist affinity for brain [3H]DPCPX binding sites and, in order of increasing significance, the equivalent behavioral dose (EBD) for reversal of CPA-induced hypolocomotion (r2 = 0.32), the serum concentration of drug (r2 = 0.65), and most significantly with the brain concentration of drug detected 20 min after administration of the (EBD) (r2 = 0.95). These data suggest that competition between agonists and antagonists, for occupancy of central adenosine A1 receptors, is intrinsic to the pharmacological reversal of CPA-induced hypolocomotion. The validity of the model as a simple predictive screen for the blood/brain barrier permeability of adenosine A1 receptor antagonists was thereby confirmed.
Footnotes
-
Send reprint requests to: Dr. H. M. Marston, Fujisawa Institute of Neuroscience, Department of Pharmacology, University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, UK.
-
↵1 The work was supported by the Fujisawa Pharmaceutical Co., Japan. A Medical Research Council, UK studentship, supported K. F.
- Abbreviations:
- APEC
- 2-[(2-aminoethylamino)carbonylethyl-phenylethylamino]-5′-ethylcarboxamido adenosine
- CADO
- 2-chloroadenosine
- CHA
- N6-cyclohexyladenosine
- CPA
- N6-cyclopentyladenosine
- NECA
- 5′-N-ethylcarboxamidoadenosine
- R-PIA
- R(-)N6-(2-phenylisopropyl)adenosine
- 8-PST
- 8-(p-sulphophenyl)-1,3-dimethylxanthine
- 8-PT
- 8-phenyl-1,3-dimethylxanthine
- caffeine
- 1,3,7-trimethylxanthine
- CPT
- 8-cyclopentyl-1,3-dimethylxanthine
- DPCPX
- 8-cyclopentyl-1,3-dipropylxanthine
- DPSPX
- 8-(p-sulphophenyl)-1,3-dipropylxanthine
- DPX
- 8-phenyl-1,3-diethylxanthine
- FK352
- (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-acryloyl]-piperidin-2-yl acetic acid
- FK453
- (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-acryloyl]-2-piperidine ethanol
- FR160492
- 1-benzyl-1-6-(4-methoxyphenyl)-3-propyl-1,2,3,4-tetrahydro-5H-imidazol[2′,1′:5,1] pyrazolo[3,4-d] pyrimidin-2,4-dione
- KF17837
- (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine
- KW3902
- 8-(noradamantan-3-yl)-1,3-dipropylxanthine
- MDL102234
- (R)-1,3-dipropyl-8-(1-phenylpropyl)xanthine
- theophylline
- 1,3-dimethylxanthine
- CNS
- central nervous system
- EBD
- equivalent behavioral dose
- DMSO
- dimethylsulphoxide
- Received July 15, 1997.
- Accepted February 16, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|